英夫利西单抗辅助治疗双相I/II型抑郁的随机临床试验
这项12周随机双盲安慰剂对照试验纳入60例有炎症激活证据的双相I/II型抑郁成人,评估英夫利西单抗辅助治疗的抗抑郁疗效。主要结局MADRS总分从基线至第12周变化在治疗×时间交互上显著,但第12周症状严重度降低不显著;二次分析显示有童年躯体虐待史者接受英夫利西西单抗后MADRS减分和应答率更高。
要点
- 英夫利西单抗辅助治疗未显著降低双相抑郁总体症状严重度。
- 治疗×时间交互显著,提示症状变化轨迹可能因治疗而异。
- 有童年躯体虐待史者接受英夫利西单抗后MADRS减分及应答率更高。
核心结论
- 英夫利西单抗与安慰剂相比未显著降低双相抑郁成人的抑郁症状。
- 二次分析识别出报告躯体/性虐待史的亚组,英夫利西单抗治疗较安慰剂显著降低抑郁症状。
研究设计与样本
- 12周随机双盲安慰剂对照平行组试验,在加拿大和美国2个门诊三级医疗点开展。
- 60例18-65岁符合DSM-5双相I或II型抑郁且治疗前有生化/表型炎症激活证据的成人被随机分配。
- 干预为基线及第2、6周静脉输注英夫利西单抗或安慰剂,共3次。
- 主要疗效结局为基线至第12周MADRS总分变化,采用改良意向性分析。
主要发现
- 总体基线至终点MADRS总分变化在治疗×时间交互上显著(χ2=10.33;P=.04)。
- 第12周症状严重度降低不显著(相对危险度1.09;95%CI 0.80-1.50;df=1;P=.60)。
- 二次分析中治疗×时间×童年虐待交互显著,英夫利西单抗组有童年躯体虐待史者MADRS总分减分更大(χ2=12.20;P=.02)。
- 该亚组应答率(MADRS总分降低≥50%)更高(χ2=4.05;P=.04)。
关键数值与推荐
- 入组标准为DSM-5双相I或II型抑郁且治疗前有生化/表型炎症激活证据。
- 主要结局为基线至第12周MADRS总分变化。
- 应答定义为MADRS总分降低≥50%。
临床怎么用
- 对总体双相抑郁人群,英夫利西单抗辅助治疗未显示显著抗抑郁疗效。
- 对有童年躯体/性虐待史的双相抑郁患者,英夫利西单抗可能带来更明显的症状改善,但需进一步验证。
局限性
- 样本量较小(60例),二次分析结果需谨慎解读。
- 研究仅纳入有炎症激活证据的双相抑郁成人,外推受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: To our knowledge, no study has previously evaluated whether individuals with bipolar depression enriched a priori on the basis of biochemical and/or phenotypic immuno-inflammatory activation would differentially respond to an anti-inflammatory agent for the treatment of depressive symptoms. OBJECTIVE: To assess the antidepressant efficacy of adjunctive infliximab, a monoclonal antibody targeting tumor necrosis factor, in adults with bipolar I and bipolar II depression and inflammatory conditions. DESIGN, SETTING, AND PARTICIPANTS: This 12-week, randomized, double-blind, placebo-controlled, parallel-group trial of 60 participants was conducted at 2 outpatient tertiary care sites in Canada and the United States. Eligible adults (aged 18-65 years) met DSM-5-defined criteria for bipolar I or bipolar II depression and exhibited pretreatment biochemical and/or phenotypic evidence of inflammatory activation. Participants were enrolled between October 1, 2015, and April 30, 2018. Data analysis was performed from May 1 through July 31, 2018, using modified intent-to-treat analysis. INTERVENTIONS: Patients were randomized to receive 3 intravenous infusions of infliximab therapy or placebo at baseline and at weeks 2 and 6 of the 12-week study. MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was baseline-to-end point (ie, week-12) change in Montgomery-Asberg Depression Rating Scale (MADRS) total score. History of childhood maltreatment, as assessed by the Childhood Trauma Questionnaire, was used for exploratory analyses as 1 of several secondary outcomes. RESULTS: A total of 60 participants were randomized to infliximab (n = 29 [48%]; mean [SD] age, 45.0 [11.7] years; 20 of 28 female [71%]) or to placebo (n = 31 [52%]; mean [SD] age, 46.8 [10.2] years; 26 of 30 female [87%]) across study sites. Overall baseline-to-end point change in MADRS total score was observed across treatment × time interaction (χ2 = 10.33; P = .04); reduction in symptom severity was not significant at week 12 (relative risk, 1.09; 95% CI, 0.80-1.50; df = 1; P = .60). As part of a secondary analysis, a significant treatment × time × childhood maltreatment interaction was observed in which infliximab-treated individuals with childhood history of physical abuse exhibited greater reductions in MADRS total score (χ2 = 12.20; P = .02) and higher response rates (≥50% reduction in MADRS total score) (χ2 = 4.05; P = .04). CONCLUSIONS AND RELEVANCE: Infliximab did not significantly reduce depressive symptoms compared with placebo in adults with bipolar depression. Results from secondary analyses identified a subpopulation (ie, those reporting physical and/or sexual abuse) that exhibited a significant reduction in depressive symptoms with infliximab treatment compared with placebo. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02363738.
引用
- McIntyre RS, Subramaniapillai M, Lee Y, et al. Efficacy of Adjunctive Infliximab vs Placebo in the Treatment of Adults With Bipolar I/II Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2019. PMID: 31066887. doi:10.1001/jamapsychiatry.2019.0779
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。